Kissei Pharmaceutical Co., Ltd.
4547.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥25,169,000 | ¥22,894,000 | ¥25,893,000 | ¥30,013,000 |
| Short-Term Investments | ¥23,485,000 | ¥23,039,000 | ¥23,706,000 | ¥23,139,000 |
| Receivables | ¥29,653,000 | ¥28,679,000 | ¥22,806,000 | ¥22,806,000 |
| Inventory | ¥24,979,000 | ¥26,296,000 | ¥22,798,000 | ¥18,987,000 |
| Other Curr. Assets | ¥3,694,000 | ¥3,643,000 | ¥5,438,000 | ¥4,397,000 |
| Total Curr. Assets | ¥106,980,000 | ¥104,551,000 | ¥100,641,000 | ¥99,342,000 |
| Property Plant & Equip (Net) | ¥27,069,000 | ¥24,861,000 | ¥24,579,000 | ¥24,074,000 |
| Goodwill | ¥242,000 | ¥309,000 | ¥0 | ¥0 |
| Intangibles | ¥1,652,000 | ¥1,683,000 | ¥1,507,000 | ¥1,569,000 |
| Long-Term Investments | ¥84,874,000 | ¥106,366,000 | ¥51,063,000 | ¥96,634,000 |
| Tax Assets | ¥566,000 | ¥608,000 | ¥433,000 | ¥524,000 |
| Other NC Assets | ¥22,676,000 | ¥22,551,000 | ¥42,974,000 | ¥15,941,000 |
| Total NC Assets | ¥137,079,000 | ¥156,378,000 | ¥120,556,000 | ¥138,742,000 |
| Other Assets | ¥0 | ¥5,000 | ¥3,000 | ¥3,000 |
| Total Assets | ¥244,059,000 | ¥260,929,000 | ¥221,200,000 | ¥238,087,000 |
| Liabilities | – | – | – | – |
| Payables | ¥4,602,000 | ¥4,893,000 | ¥4,617,000 | ¥4,104,000 |
| Short-Term Debt | ¥1,280,000 | ¥1,340,000 | ¥1,490,000 | ¥1,640,000 |
| Tax Payable | ¥0 | ¥2,380,000 | ¥408,000 | ¥3,497,000 |
| Deferred Revenue | ¥1,033,000 | ¥1,486,000 | ¥4,082,000 | ¥8,051,000 |
| Other Curr. Liab. | ¥9,663,000 | ¥7,564,000 | ¥4,360,000 | ¥1,452,000 |
| Total Curr. Liab. | ¥16,578,000 | ¥17,663,000 | ¥14,957,000 | ¥18,744,000 |
| LT Debt | ¥166,000 | ¥0 | ¥0 | ¥0 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Tax Liab, NC | ¥16,481,000 | ¥21,188,000 | ¥10,426,000 | ¥16,259,000 |
| Other NC Liab. | ¥705,000 | ¥944,000 | ¥1,004,000 | ¥906,000 |
| Total NC Liab. | ¥17,352,000 | ¥22,132,000 | ¥11,430,000 | ¥17,165,000 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥166,000 | ¥0 | ¥0 | ¥0 |
| Total Liabilities | ¥33,930,000 | ¥39,795,000 | ¥26,387,000 | ¥35,909,000 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥161,247,000 | ¥153,854,000 |
| Common Stock | ¥24,356,000 | ¥24,356,000 | ¥24,356,000 | ¥24,356,000 |
| Retained Earnings | ¥131,488,000 | ¥127,310,000 | ¥125,576,000 | ¥118,183,000 |
| AOCI | ¥43,453,000 | ¥57,344,000 | ¥32,652,000 | ¥47,530,000 |
| Other Equity | ¥9,707,000 | ¥11,017,000 | ¥11,314,000 | ¥11,314,000 |
| Total Equity | ¥209,004,000 | ¥220,027,000 | ¥193,899,000 | ¥201,384,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥1,122,000 | ¥1,107,000 | ¥914,000 | ¥794,000 |
| Total Liab. & Tot. Equity | ¥244,059,000 | ¥260,929,000 | ¥221,200,000 | ¥238,087,000 |
| Net Debt | -¥23,723,000 | -¥21,554,000 | -¥24,403,000 | -¥28,373,000 |